Skip to main content
. 2020 Jul 13;14(10):2646–2659. doi: 10.1002/1878-0261.12745

Fig. 5.

Fig. 5

The positive rate of EV‐LINC00853 in all‐stage and early‐stage HCC. (A) The rate of positive results of AFP and EV‐LINC00853 in patients with each liver disease status. The cutoff for positivity was defined as a 14‐fold increase in EV‐LINC00853 expression, and 20 ng·mL−1 for AFP level. (B) The rate of positive results for EV‐LINC00853 by AFP status in patients with HCC. (C) The rate of positive results for EV‐LINC00853 by AFP status in patients with mUICC I/II. (D) The rate of positive results for EV‐LINC00853 by AFP status in patients with mUICC I. Target gene expression was calculated relative to that of HMBS.